Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd.
Date:9/5/2008

XI'AN, China, Sept. 5 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB) (the "Company"), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production in Xi'an, China, is pleased to announce a Letter of Intent to enter into a contractual arrangement with Xi'an Qinba Xintong Medical Ltd. ("Qinba"). Under the proposed terms of this arrangement, Huifeng will take over operational control of Qinba and will receive a management fee equal to all of Qinba's profit.

"As a manufacturer of finished medical devices, Qinba will give Huifeng immediate access to pharmacy and medicine buyers," stated Huifeng's CEO and founder Jing'An Wang. "With this Letter of Intent, Huifeng has taken the first step toward positioning itself for synergistic growth beyond its core revenue base."

Mr. Wang further noted that Huifeng is now commencing a vertical integration strategy intended to transform the company from a producer of raw materials for the Traditional Chinese Medicine industry to a full-scale pharmaceutical company supplying end products to consumers worldwide.

"With this Letter of Intent, we have proven our ability to attract accretive deals within the People's Republic of China," continued Mr. Wang. "Moving forward, we hope to close on several larger strategic partnerships."

Huifeng is maintaining its guidance for $18M in revenue and $4M of net income.

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties in Xi'an China. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/

This press release may contain forward-looking statements. These statements are based on the current expectations or beliefs of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements, including but not limited to the fluctuation of prices of raw materials, the market demand for our products, changes in governmental regulations and/or economic policies and our ability to penetrate new markets.

For more information, please contact:

Dan Carlson, Primary Capital LLC

Email: DCarlson@PrimaryLLC.com

Kelly Black, CEO Premier Media Services, Inc.

Tel: +1-480-649-8224

Email: kblack@premiermediaserice.com


'/>"/>
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
4. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
5. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
6. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
7. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
8. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
9. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
10. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
11. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Scientists at ... line options being tried for mesothelioma may be hampering the research that could lead ... research. Click here to read it now. , The team evaluated 98 ...
(Date:5/24/2016)... ... 24, 2016 , ... Cell therapies for a range of ... research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method of ... The novel method, developed by WPI faculty members Raymond Page, PhD, professor of ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across ... South Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations ... are down 21 percent in South Texas in the last four years alone. , There ...
(Date:5/23/2016)... and LONDON , May 23, 2016 ... Frontage Boost Efficiency by 40% - Frontage Implement a ... Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... in the United States and ... be deployed across its laboratory facilities. In addition to serving as ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):